Find a company
Search the SBRI Healthcare and NHS Cancer Programme Innovation Open call portfolio.
If you would like further information on any of the companies listed in the Directory please contact the SBRI Healthcare PMO by email sbri@lgcgroup.com or tel: +44 20 8843 8125.
We would be happy to make introductions to the companies or provide any further feedback you require.
At a glance
Directory search results
CEXAL Ltd
| Project | Development of a rapid and modular phenotypic test for quantitative Urinary Tract Infection detection and antimicrobial susceptibility in 30 minutes |
|---|---|
| Description |
The technology behind FluoCDx leverages modular DNA probes, customizable for precise species recognition and broad gram-type bacterial detection. Within 5 minutes of adding a sample, the initial fluorescence signal quantitatively confirms infection. After 30 minutes, changes in fluorescence reveal antibiotic susceptibility: an increase indicates resistance, while a decrease or stable signal confirms susceptibility. This innovative approach ensures rapid, reliable diagnostics, enabling precise treatment decisions. |
| Funding | £ 99,999 |
| Competition | Competition 25 - AMR |
| Competition Date | July 2024 |
| Categories | Antimicrobial Resistance (AMR) |
| Website | https://www.cexal.com/ |
University of Bristol
| Project | A Novel Approach to Preventing Encrustation and Infection in Long-term Indwelling Urinary Catheters |
|---|---|
| Description |
Our technology will provide an alternative to existing technologies to reduce urinary catheter blockage and infections. It is cheaper, more efficient and does not require the use of any antibiotics, thereby eliminating the possibility of promoting antimicrobial resistance development or lacking efficacy against AMR bacteria. |
| Funding | £ 81,286 |
| Competition | Competition 25 - AMR |
| Competition Date | July 2024 |
| Categories | Antimicrobial Resistance (AMR) |
| Website | https://www.bristol.ac.uk/ |
Presymptom Health Limited
| Project | Development of the InfectiClear test onto Near Patient and Point-of-Care NHS |
|---|---|
| Description |
Presymptom Health machine-learning-derived blood tests investigate the patient – rather than the pathogen – allowing us to rule out infection or sepsis. Existing technologies are slow (up to 3 days to result) and fail to distinguish pathogenicity from colonization. Presymptom Health is developing a patented set of assays to support early diagnosis and enhanced antibiotic stewardship to combat the Anti Microbial Resistance (AMR) crisis. Trained from blood samples collected over 15 years, these samples included thousands of patients, some of whom developed infections and sepsis. The first product, InfectiClear®, will be available from 2025. |
| Funding | £ 99,993 |
| Competition | Competition 25 - AMR |
| Competition Date | July 2024 |
| Categories | Antimicrobial Resistance (AMR) |
| Website | https://www.presymptom.com/ |